PMDD
9
3
3
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
11.1%
1 terminated out of 9 trials
50.0%
-36.6% vs benchmark
11%
1 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (9)
Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause
MLS101 Study in PMDD
The SPARK-PMDD Study
Identification and Validation of Epigenetic Biomarkers of PMDD
Evaluating the Impact of Psychoeducation and Sleep-informed Workshop Targeting Sleep Concerns in Women and Individuals With Premenstrual Dysphoric Disorder
Microdosing LSD in Women With Premenstrual Disorders
Stress & Premenstrual Symptoms Study
Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Disorder
Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives